3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
545
Lymphoma
444
Precursor Cell Lymphoblastic Leukemia-Lymphoma
409
Lymphoma, Large B-Cell, Diffuse
347
Leukemia
344
Multiple Myeloma
335
Lymphoma, Non-Hodgkin
316
Leukemia, Myeloid, Acute
288
Leukemia, Lymphocytic, Chronic, B-Cell
285
Lymphoma, Follicular
240
Burkitt Lymphoma
217
Myelodysplastic Syndromes
209
Lymphoma, Mantle-Cell
201
Hodgkin Disease
193
Recurrence
153
Lymphoma, B-Cell, Marginal Zone
142
Melanoma
135
Lymphoma, Large-Cell, Immunoblastic
116
Neoplasms
109
Lymphoma, B-Cell
103
Neuroblastoma
101
Neoplasms, Plasma Cell
99
Ovarian Neoplasms
96
Triple Negative Breast Neoplasms
93
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
91
Myeloproliferative Disorders
87
Hematologic Neoplasms
87
Leukemia, Myeloid, Chronic-Phase
83
Leukemia, Myeloid, Accelerated Phase
80
Leukemia, Myelomonocytic, Chronic
78
Interventions
Nivolumab
14
Ipilimumab
11
Specimen Handling
9
CTLA-4 Antigen
7
pembrolizumab
6
cabozantinib
6
Magnetic Resonance Spectroscopy
6
Sunitinib
5
Axitinib
5
pazopanib
4
Biopsy
4
Radiosurgery
3
lenvatinib
2
fludarabine
2
Everolimus
2
tivozanib
1
sodium-iodide symporter
1
sitravatinib
1
belzutifan
1
atezolizumab
1
aldesleukin
1
Zoledronic Acid
1
Selenomethionine
1
Radiotherapy
1
Radiopharmaceuticals
1
Pluvicto
1
Nephrectomy
1
Metastasectomy
1
LY2510924
1
Inulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Clear-cell metastatic renal cell carcinoma
×
Cyclophosphamide
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled